Close this search box.

Early clinical data lift Sana’s shares, though CAR T’s durability remains unproven

ARTICLE | Product Development

Cell therapy derived from hypoimmune platform leads to responses without serious side effects, driving up company’s value

By Paul Bonanos, Director of Biopharma Intelligence

January 11, 2024 9:25 PM UTC

Shares of cell therapy company Sana ticked up this week after the company presented early clinical evidence of efficacy for its hypoimmune, allogeneic CAR T therapy in blood cancer patients. But despite some encouraging antitumor efficacy, the results don’t yet show proof that the therapies produce durable responses to validate the company’s thesis.

Sana Biotechnology Inc. (NASDAQ:SANA) is hoping to show that its hypoimmune platform can help overcome rejection of allogeneic cell therapies, giving them a durability advantage. The company has four clinical programs across seven indications in cancer, autoimmune disorders and diabetes…